 European Federation of Endocrine Societies |
 |
| October 2004 News Alert | http://www.euro-endo.org |
|
||||||||||||||||||
| http://www.euro-endo.org/news/news.htm | ||||||||||||||||||
ANNOUNCING
ECE2006, Glasgow, UK Co Chairing the Programme Organising Committee are Dr P Bouloux (London) and Dr J Köhrle (Berlin). Further information will be available on line at http://www.ece2006.com soon. For information
on the City of Glasgow go to: http://www.seeglasgow.com/ |
||||||||||||||||||
 |
||||||||||||||||||
Still
some places left for postgraduate course! The programme will include cutting edge lectures and practical interactive workshops in small groups on diabetes, indications of parathyroidectomy, thyroid cancer, investigation of thyroid function, arteriosclerosis, hyperandrogenism, androgen resistence, acromegaly, aging, indications of radiotherapy and quality of life. The venue on the sea front will allow a relaxed atmosphere between the scientific sessions. Find registration
information at: http://www.euro-endo.org/courses/courses.htm |
||||||||||||||||||
|
||||||||||||||||||
New
issue of efes news – out now! If you are a
member of any of the European national endocrine societies, you
should receive a free copy of EFES News each spring and autumn.
If you are not receiving this and would like to, please send your
full name and address to: jane.shepley@endocrinology.org |
||||||||||||||||||
|
||||||||||||||||||
EFES
Website The EFES Executive
Committee sincerely appreciate your time and look forward to hearing
from you. |
||||||||||||||||||
|
||||||||||||||||||
| Assisting
European researchers across the Atlantic ERA-Link is a network currently being designed with the aim of assisting European researchers working in the United States. The service will provide web and other resources for scientists wishing to develop links with other European researchers working in the US and Europe. An online survey has been launched to help the European Commission and the European Embassies in Washington understand how the service should be developed to be most useful to researchers working abroad. You
can find the survey at: http://www.evaluationpartnership.com/surveys/eralink.htm
|
||||||||||||||||||
|
||||||||||||||||||
| EC
aims to promote development of paediatric medicines More than 50% of the medicines used to treat children have not been specifically tested and authorised for use in children. This means that doctors may not be fully aware of efficacy, dosage and side effects of these drugs in children. The Commission has proposed a regulation for the research and development of pharmaceuticals specifically designed to meet specific paediatric needs, whilst enabling continuing competitiveness within the pharmaceutical industry. Key elements in the proposal include: a new expert committee within the European Medicines Agency to assess and agree companies’ testing plans; a requirement at the time of marketing authorisation applications for data on the use of the medicine in children; and a reward for studying medicines for children of 6-months extension to the supplementary protection certificate - in effect, six-month patent extension. The
full text of the proposal is available at: http://pharmacos.eudra.org/F2/Paediatrics/index.htm |
||||||||||||||||||
|
||||||||||||||||||
| European
Rare Disease Therapeutic Initiative (ERDITI) – call for proposals Collectively, there are over 6000 rare diseases affecting about 25 million people in Europe. Most do not benefit from efficient treatment. In order to address this problem, through promoting research and developing drugs for the treatment of rare diseases, several European academic institutions and pharmaceutical companies have joined forces in an innovative partnership to facilitate the evaluation of drugs that have been or are being developed by pharmaceutical companies. All non-profit research institutions from European countries and pharmaceutical companies are invited to join ERDITI. ERDITI has issued a call for proposals intended for European academic scientists working on a rare disease, or a defined group of rare diseases, and who would like access to compounds that have been or are being developed by pharmaceutical companies. Proposals should address the specific evaluation of chosen compounds in vitro or in animal models, based on pharmacological and/or physiopathological hypothesis. To find
out more information, go to: http://www.erditi.org/ |
||||||||||||||||||
|
||||||||||||||||||
| Five-year
assessment of EU research The Commission has launched an Independent Assessment Report of recent research programmes. Spanning the period 1999-2003, the review will cover the end of FP5 and the beginning of FP6. The assessment will consider the implementation and evolution of programmes in order to inform future research policy, including helping to shape FP7. By analysing the achievements of past and current EU activities, the group of 13 leading scientists and engineers from 13 countries will aim to provide evidence-based support to improve the relevance and quality of Community research activities. The report should be available by November 2004. |
||||||||||||||||||
|
||||||||||||||||||
| http://www.eje.org/ | ||||||||||||||||||
| LATEST EJE IMPACT FACTOR 2.941 Impaired
health-related quality of life in Graves' disease. A prospective
study European
Journal of Endocrinology 151(5) pp549-555 Graves’ thyrotoxicosis can affect patients’ lives for months, and sometimes years, before diagnosis and the symptoms experienced during the acute phase of the disease often persist for up to 6 months after the start of treatment. During this period a patient’s health-related quality of life (HRQOL) might be significantly impaired. In the first prospective study to report on the HRQOL of consecutively referred patients with untreated Graves’ disease without comorbidity, Elberling and co-workers reveal the extent to which the patients’ lives are affected. Using the Medical Outcome Study 36-item Short-Form Health Status Survey (SF-36) to assess each patient’s HRQOL, Elberling and co-workers report that following diagnosis and treatment the SF-36 scores generally improved but, in some cases, patients’ HRQOL remained impaired even 1 year after the start of treatment. The reduced HRQOL in the acute phase of the disease correlated to depressive and anxiety symptoms. The authors also report that patients in some retrospective studies report long-term neuropsychiatric symptoms despite successful antithyroid treatment. This progressive study concludes that a clear explanation for patients still experiencing impaired HRQOL after 1 year of treatment remains to be found, and advises that not only thyroid function but also HRQOL should be considered when treating patients with Graves’ disease. |
||||||||||||||||||
|
||||||||||||||||||
| WADA
funding available for research into insulin abuse The World Anti-Doping Agency (WADA) is the international body that investigates the use of drugs in sport. It is interested in sponsoring research into "Methods to distinguish exogenous and endogenous insulin in biological material". If
you have specific expertise in this area, please contact Ann-Muriel
Steff (ann-muriel.steff@wada-ama.org) for more information. |
||||||||||||||||||
|
||||||||||||||||||
| EURYI
(European Young Investigator) Awards. Second call for proposals The European Union Research Organisations Heads of Research Councils (EUROHORCs) developed the European Young Investigator (EURYI) Awards in collaboration with the European Science Foundation. The aim of EURYI Awards will be to enable and encourage outstanding young researchers from all over the world, to work in a European environment and lead their own research team. The main selection criteria to be used by EURYI Awards will be scientific quality, originality and potential. The EURYI Awards shall foster innovative research, novel scientific problems and/or novel methodologies. Applicants should have an excellent track record with the potential to become world class leaders in their respective field of research. Awards will last for up to 5 years and the total value will be between 750,000 and 1,250,000 Euros. In July 2004 25 awards were granted after the first call. The second call has a deadline of 30 November 2004. For more information go to: http://www.esf.org/esf_genericpage.php?section=8&domain=0&genericpage=1879 |
||||||||||||||||||
|
||||||||||||||||||
| Geoffrey Harris
Prize We have pleasure in announcing the 2005 Geoffrey Harris Prize generously sponsored by Ipsen. This prestigious prize is designed for established researchers in the field of neuroendocrinology and is the first of its kind in Europe. Please contact the EFES Secretary: Prof. Dr. J. Köhrle Institut für Experimentelle Endokrinologie und Endokrinologisches Forschungs-Centrum Charité - Hochschulmedizin Berlin, Campus Mitte Schumannstr. 20/21 D-10098 Berlin Germany Tel: +49 30 450524021 Fax: +49 30 450525922 Email: josef.koehrle@charite.de or elke.abdel-karim@charite.de The deadline for entries is 31 December 2004 and the award will be presented at the 7th European Congress of Endocrinology which takes place from 3-7 September 2005 in Göteborg, Sweden. More information is available on: http://www.euro-endo.org/about/harrisprize.htm |
||||||||||||||||||
|
||||||||||||||||||
European
Journal of Endocrinology Prize Nominations
should be submitted to:- The deadline for entries is 31 December 2004. More information on the prize and nomination process is available on http://www.eje.org/eje/ejeprize.htm |
||||||||||||||||||
|
||||||||||||||||||
| National
Institute on Aging planning project for testosterone trials in aging
men The National Institute on Aging (NIA) invites applications for planning and protocol development of a coordinated set of clinical trials of efficacy and safety of testosterone treatment in older men for specific symptomatic conditions that may be related to low testosterone levels, and of effects of testosterone treatment in middle-aged men on outcomes and risk factors possibly related to low testosterone levels. The NIA intends to commit up to $700,000 in total costs in FY 2005 to fund one award. The award will support planning activities, biostatistical and other data analyses needed for trials design, and protocol development. Deadline
for expressions of interest is 10 December 2004. Deadline for applications
is 11 January 2005 |
||||||||||||||||||
|
||||||||||||||||||
| ASCO
Foundation International Travel Grants (ITG) American Society of Clinical Oncology will be awarding 20 travel grants to oncologists from countries of limited resources that meet the eligibility requirements. The monetary award is designed to cover expenses (coach airfare, hotel, and meals) in order to attend the ASCO Annual Meeting in Orlando, Florida, May 2005. Grant recipients will also receive complimentary meeting registration, some tickets to sessions, and invitations to special ITG events (such as, a tour of a comprehensive cancer center, opening reception, etc.) The deadline for applications is 14 January 2005. To review criteria and apply for the 2005 ITG Program visit http://www.asco.org/itg |
||||||||||||||||||
|
||||||||||||||||||
| Serono
Foundation 2005 Fellowship in Reproductive Endocrinology Since 1997, the Serono Foundation has granted two to three fellowships every year to promising young scientists. The fellowships' laureates receive USD 45,000 every year for two years to fund research for a full-time postdoctoral training programme. In 2005 fellowships will be awarded by the Serono Foundation for postdoctoral training pertaining to the research area of reproductive endocrinology. The 2005 Fellowship will be awarded on or before 15 July 2005. Deadline for applications is 28 February 2005. For more information go to: http://www.serono-foundation.org/fellowships.htm |
||||||||||||||||||
|
||||||||||||||||||
| Fourth
IOF-SERVIER Young Investigator Research Award The IOF-SERVIER Research Award is a grant of 40 000 Euros awarded every 2 years to a project within the field of osteoporosis. The award is aimed at encouraging young scientists and therefore is limited to applicants up to 40 years of age. The Award is officially granted during the IOF World Congress on Osteoporosis to which the winner is invited. Deadline
for submission of completed applications: 1 December 2005 |
||||||||||||||||||
|
||||||||||||||||||
| Current
NIH grants Exploratory grant program in diabetes endocrinology and metabolism http://grants.nih.gov/grants/guide/pa-files/PA-04-137.html Ubiquitin and Ubiquitin-like modifications regulating
disease processes Emerging technologies for the study of reproductive
neuroendocrinology Proteomics in diabetes and other endocrine and metabolic
diseases |
||||||||||||||||||
|
||||||||||||||||||
| Jobs
and Grants Forum on the EFES website Attention jobseekers! Post your details on the site. Attention employers! Advertise jobs or search for suitable candidates online. Attention funders! Add your grant to the EFES forum. Go to: http://www.euro-endo.org/jobsgrants/jobs.htm |
||||||||||||||||||
|
||||||||||||||||||
| Shire
launch first topical cream for hirsutism Shire Pharmaceuticals launched Vaniqa® (eflornithine 11.5% cream), the first topical prescription medicine to slow the growth of excessive facial hair in women, in the UK on 13 October 2004. Vaniqa® specifically and irreversibly inhibits ornithine decarboxylase, an enzyme critical for hair growth. |
||||||||||||||||||
|
||||||||||||||||||
| Development
begins on oral formulation of human growth hormone Emisphere Technologies Inc. have announced that they will be working with Novartis Pharma AG to initiate clinical trials of a convenient, oral human growth hormone product using their eligen® technology. Novartis will fully fund the program including all clinical studies. |
||||||||||||||||||
|
|
||||||||||||||||||
|
||||||||||||||||||
| http://www.euro-endo.org/conferences/congress.htm | ||||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||
| http://www.euro-endo.org/courses/courses.htm | ||||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||